For people living with post-traumatic stress disorder (PTSD), sleep can become a nightly reenactment of catastrophe. Traumatic memories may return as vivid, emotionally overwhelming nightmares, triggering panic, rapid arousal and repeated awakenings. The resulting sleep deprivation can intensify anxiety and impair daytime functioning, while fear of going to bed becomes another burden. A randomized clinical trial led by researchers at Charité – Universitätsmedizin Berlin now suggests that dronabinol, a prescription formulation of the cannabis compound tetrahydrocannabinol (THC), may substantially reduce trauma-related nightmares for many patients.
The study, published in Nature Medicine, enrolled more than 170 adults with PTSD and frequent, severe nightmares. Participants received either dronabinol or an identical-looking placebo every evening for ten weeks. The medication was administered as drops and contained THC derived directly from the cannabis plant. Because neither the participants nor the healthcare professionals knew which treatment had been assigned, the trial used a double-blind, placebo-controlled design, widely regarded as the most reliable method for testing whether an intervention produces effects beyond expectation, natural recovery or clinical attention.
At the end of the treatment period, nightmare severity had fallen significantly more in the dronabinol group than in the placebo group. On a scale ranging from zero to eight, the average nightmare burden declined by 3.7 points among those receiving the cannabinoid, compared with 2.2 points in the placebo arm. Although placebo responses can be substantial in studies involving sleep and mental health, the difference between the groups indicated that dronabinol provided an additional, clinically meaningful benefit for many participants.
The response was especially striking for patients whose nights had been dominated by repeated trauma-related dreams. More than one-third of participants treated with dronabinol reported that their nightmares had disappeared completely after ten weeks. A further 21 percent said that their nightmare burden had been reduced by at least half. Approximately five out of six people in the dronabinol group also reported a marked improvement in their overall health. These findings suggest that the treatment did not merely alter dream content but may have restored a degree of restorative sleep that patients had lost.
THC acts primarily through cannabinoid receptors in the body’s endocannabinoid system, a signaling network involved in sleep regulation, stress responses, emotional learning and memory processing. The compound can influence neural activity in regions implicated in fear and arousal, including circuits connecting the amygdala, hippocampus and prefrontal cortex. Researchers believe that its effects during rapid eye movement, or REM, sleep may be particularly relevant. REM sleep is associated with vivid dreaming and the processing of emotional experiences. According to the study team, THC may reduce excessive dream activity and dampen the nocturnal stress responses that cause patients to relive traumatic events with overwhelming intensity.
The researchers emphasize, however, that the cannabinoid did not appear to treat every dimension of PTSD. Changes in the overall severity of PTSD symptoms and accompanying depression were not conclusive. The clearest benefits involved nightmares and sleep-related distress. This distinction is important because PTSD is a complex disorder involving persistent avoidance, intrusive memories, negative changes in mood and cognition, and heightened vigilance. A therapy that reduces nightmares may therefore be valuable as one component of treatment without replacing trauma-focused psychotherapy or other established interventions.
Current pharmacological approaches for PTSD commonly include antidepressants and, in some cases, medications that affect blood pressure or adrenergic signaling. These treatments can help certain patients, but their effects on trauma-related nightmares are often limited. Germany does not yet have an approved medication specifically indicated for PTSD nightmares. Dronabinol is already available for selected medical uses, including situations involving severe pain when standard options are ineffective or poorly tolerated. Its use in PTSD remains a specialized approach requiring medical supervision, particularly because THC can affect alertness, perception, coordination and cardiovascular function.
In the Charité-led trial, no severe adverse effects were attributed to the treatment, and the investigators did not observe withdrawal symptoms after the evening doses were stopped. Mild or moderate side effects, including dizziness, headache and increased appetite, occurred more frequently among participants receiving dronabinol. The absence of withdrawal symptoms during the study period is reassuring, but it does not establish that long-term use carries no risk. THC-containing medicines can produce unwanted psychoactive effects in some people, and the balance between benefit and tolerability may vary according to dose, age, psychiatric history and other medications.
The researchers now plan to investigate whether the benefits remain stable over longer periods and whether tolerance develops with continued treatment. That question is central because the endocannabinoid system can adapt to repeated exposure, potentially reducing the effect of a drug over time. Longer studies will also be needed to clarify the ideal dose, identify which patients are most likely to respond, and determine whether improved sleep eventually leads to broader reductions in PTSD-related impairment. For now, the results offer a promising, targeted avenue for patients whose most disabling symptom is the nightly return of trauma.
Subject of Research: The use of dronabinol, a THC-containing prescription medication, to treat trauma-related nightmares in people with post-traumatic stress disorder.
Article Title: Dronabinol Reduces PTSD Nightmares in Randomized Clinical Trial
News Publication Date: August 5, 2026
Web References: https://doi.org/10.1038/s41591-026-04546-9
References: Roepke S et al. “Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial.” Nature Medicine. Published August 5, 2026. DOI: 10.1038/s41591-026-04546-9
Keywords: PTSD, post-traumatic stress disorder, nightmares, dronabinol, THC, cannabis-based medicine, sleep, REM sleep, trauma, psychiatric research, Nature Medicine
Tags: cannabis and PTSD researchcannabis-based therapy for traumaclinical trial PTSD sleepdouble-blind placebo-controlled PTSD studydronabinol for nightmaresinnovative treatments for PTSD nightmareslong-term effects of THC in PTSDmedical cannabis for sleep disordersPTSD sleep treatmentreduction of trauma-related nightmaressleep deprivation in PTSDTHC effects on nightmares
